Botulinum Toxin CNS Penetration for Mood Disorders
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antidepressant therapies for depressive, anxiety, and sleep disorders are associated with severe side effects and marginal efficacy, necessitating the development of new pharmaceuticals that can effectively treat these conditions without causing adverse effects.
Innovation Solution
The use of botulinum toxin compositions administered through non-intracranial routes to penetrate the central nervous system, targeting specific patient populations identified by their medical history and symptoms to enhance treatment efficacy and safety.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional antidepressant medications (monoamine oxidase inhibitors, tricyclic antidepressants, SSRIs) are used to treat depressive, anxiety, and sleep disorders, then these conditions can be addressed, but numerous severe side effects occur including hypertension, headache, gastrointestinal complications, anticholinergic effects, drowsiness, cardiac arrhythmias, weight gain, and sleep disruption
Solution Approach 1:
The patent extracts and isolates botulinum toxin as a specific therapeutic agent from traditional antidepressant classes, administering it through non-intracranial routes to achieve CNS penetration while avoiding the side effect profiles associated with conventional medications like monoamine oxidase inhibitors, tricyclic antidepressants, and SSRIs
Solution Approach 2:
The patent uses botulinum toxin as an intermediary substance that can penetrate the blood-brain barrier through non-intracranial administration routes, serving as a mediator to deliver therapeutic effects to the CNS while bypassing the harmful side effects of traditional antidepressants
2Reliability
If traditional antidepressant therapies are used, then depressive, anxiety, and sleep disorders can be treated, but the response rate is only 50-60% and the average absolute response rate between antidepressants and placebo is about 20-25%
Solution Approach 1:
The patent changes the fundamental parameter of treatment approach by introducing botulinum toxin administration through non-intracranial routes, aiming to achieve superior response rates compared to the 50-60% response rate and 20-25% absolute difference from placebo observed with traditional antidepressants
Data Source
AI summary
The invention provides methods for treating primary disorders of mood and affect, including depressive disorders, anxiety and sleep disorders and CNS disorders comprising the administration of a neurotoxin.